Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

NCT03799445 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

37

Enrollment

OTHER

Sponsor class

Stopped \<75% participation

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal Basaloid Carcinoma
Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Posterior Tongue Squamous Cell Carcinoma
Soft Palate Squamous Cell Carcinoma
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Tonsillar Squamous Cell Carcinoma

Interventions

RADIATION: Intensity-Modulated Radiation Therapy
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]